[67] M. Mangion et al., “Evaluation of novel HIV vaccine candidates using recombinant

vesicular stomatitis virus vector produced in serum-free Vero cell cultures,” Vaccine,

vol. 38, no. 50, pp. 7949–7955, Nov. 2020, doi: 10.1016/j.vaccine.2020.10.058

[68] T. W. Geisbert and H. Feldmann, “Recombinant vesicular stomatitis virus–based

vaccines against Ebola and Marburg virus infections,” J. Infect. Dis., vol. 204, no.

suppl_3, pp. S1075–S1081, 2011, doi: 10.1093/infdis/jir349

[69] A. M. Henao-Restrepo et al., “Efficacy and effectiveness of an rVSV-vectored

vaccine in preventing Ebola virus disease: Final results from the Guinea ring vac-

cination, open-label, cluster-randomised trial (Ebola Ça Suffit!),” Lancet, vol. 389,

no. 10068, pp. 505–518, 2017, doi: 10.1016/S0140-6736(16)32621-6

[70] A. M. Munis, E. M. Bentley, and Y. Takeuchi, “A tool with many applications:

vesicular stomatitis virus in research and medicine,” Expert Opin. Biol. Ther., vol.

20, no. 10, pp. 1187–1201, Oct. 2020, doi: 10.1080/14712598.2020.1787981

[71] S. Kiesslich, G. N. Kim, C. F. Shen, C. Y. Kang, and A. A. Kamen, “Bioreactor

production of rVSV-based vectors in Vero cell suspension cultures,” Biotechnol.

Bioeng., vol. 118, no. 7, pp. 2649–2659, Jul. 2021, doi: 10.1002/bit.27785

[72] T. P. Monath et al., “rVSV Delta G-ZEBOV-GP (also designated V920) re-

combinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein:

Standardized template with key considerations for a risk/benefit assessment,”

Vaccine: X, vol. 1, Apr. 2019, Art no. 100009, doi: 10.1016/j.jvacx.2019.100009

[73] C. F. Shen et al., “Development of suspension adapted Vero cell culture process

technology for production of viral vaccines,” Vaccine, vol. 37, no. 47,

pp. 6996–7002, Nov. 2019, doi: 10.1016/j.vaccine.2019.07.003

[74] A. Huttner et al., “The effect of dose on the safety and immunogenicity of the VSV

Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2

trial,” Lancet Infect. Dis., vol. 15, no. 10, pp. 1156–1166, Oct. 2015, doi: 10.1016/

s1473-3099(15)00154-1

[75] B. A. G. Coller et al., “Clinical development of a recombinant Ebola vaccine in the

midst of an unprecedented epidemic,” Vaccine, vol. 35, no. 35, pp. 4465–4469, Aug.

2017, doi: 10.1016/j.vaccine.2017.05.097

[76] J. A. Regules et al., “A recombinant vesicular stomatitis virus Ebola vaccine,” N.

Engl. J. Med., vol. 376, no. 4, pp. 330–341, Jan 2017, doi: 10.1056/NEJMoa1414216

[77] G. N. Kim, K. Wu, J. P. Hong, Z. Awamleh, and C. Y. Kang, “Creation of matrix

protein Gene variants of two serotypes of vesicular stomatitis virus as prime-boost

vaccine vectors,” J. Virol., vol. 89, no. 12, pp. 6338–6351, Jun. 2015, doi: 10.1128/

jvi.00222-15

[78] “WHO informal consultation on characterization and quality aspect of vaccines

based on live viral vectors,”Geneva: WHO HQ, Dec. 2003.

[79] “Guideline on quality, non-clinical and clinical aspects of live recombinant viral

vectored vaccines,” Committee for Medicinal Product for Human Use (CHMP), 24

Jun 2010.

Vectored vaccines

291